Toward a Personalized Use of Paclitaxel

Author(s): Gian L. Russo*.

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 14 , Issue 4 , 2019

Become EABM
Become Reviewer

[1]
Wall ME, Wani MC. 153rd National Meeting of the American Chemical Society. Miami Beach (FL). 1967; p. M-006.
[2]
Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93(9): 2325-7.
[3]
Martin V. Overview of paclitaxel (TAXOL). Semin Oncol Nurs 1993; 9(4)(Suppl. 2): 2-5.
[4]
Mekhail TM, Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother 2002; 3(6): 755-66.
[5]
Goodman J, Walsh V. The Story of Taxol: Nature and Politics in the Pursuit of an Anti-Cancer Drug. 1st ed. Cambridge University Press: New York 2001; 323: pp. (7304)115-25.
[6]
Van Hagen P, Hulshof MC, Van Lanschot JJ, Steyerberg EW, Van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative Chemo-radiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366(22): 2074-84.
[7]
Ma WW, Hidalgo M. The winning formulation: The development of paclitaxel in pancreatic cancer. Clin Cancer Res 2013; 19(20): 5572-9.
[8]
Vaughn DJ. Paclitaxel and carboplatin in bladder cancer: Recent developments. Eur J Cancer 2000; 36(Suppl. 2): 7-12.
[9]
Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am 2001; 15(3): 525-45.
[10]
Leon-Ferre RA, Markovic SN. Nab-paclitaxel in patients with metastatic melanoma. Expert Rev Anticancer Ther 2015; 15(12): 1371-7.
[11]
Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277(5698): 665-7.
[12]
Yang CH, Horwitz SB. Taxol: The first microtubule stabilizing agent. Int J Mol Sci 2017; 18(8): 1733-41.
[13]
Xin DS, Zhou L, Li CZ, Zhang SQ, Huang HQ, Qiu GD, et al. TC > 0.05 as a pharmacokinetic parameter of paclitaxel for therapeutic efficacy and toxicity in cancer patients. Recent Patents Anticancer Drug Discov 2018; 13(3): 341-7.
[14]
Zhang S, Sun M, Yuan Y, Wang M, She Y, Zhou L, et al. Correlation between paclitaxel TC > 0.05 and its therapeutic efficacy and severe toxicities in ovarian cancer patients. Cancer Transl Med 2016; 2(5): 131-6.
[15]
Gradishar WJ. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother 2006; 7(8): 1041-53.
[17]
ClinicalTrialsgov Albumin-bound paclitaxel (ABI-007) for patientswith advanced non-small cell lung cancer 2013 [Available from. https://clinicaltrials.gov/ct2/show/study/NCT00540514]
[18]
ClinicalTrialsgov Phase III study of ABI-007(Albumin-bound paclitaxel) plus gemcitabine versus gemcitabine in metastatic adenocarcinoma of the pancreas 2016 [Available from. https://clinicaltrials.gov/ct2/show/NCT00844649]
[19]
Sofias AM, Dunne M, Storm G, Allen C. The battle of “nano” paclitaxel. Adv Drug Deliv Rev 2017; 122: 20-30.
[20]
Ojima I, Lichtenthal B, Lee S, Wang C, Wang X. Taxane anticancer agents: A patent perspective. Expert Opin Ther Pat 2016; 26(1): 1-20.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 4
Year: 2019
Page: [296 - 297]
Pages: 2
DOI: 10.2174/157489281404191220161014

Article Metrics

PDF: 15
HTML: 2

Special-new-year-discount